-
Subject Areas on Research
-
A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy.
-
Adriamycin in the treatment of childhood acute leukemia. A Southwest Oncology Group study.
-
Chemoradiotherapy toxicity during bone marrow transplantation: time course and variation in pain and nausea.
-
Clinical use of oral contraceptives administered vaginally: a case report.
-
Double blind randomized trial of sucralfate vs placebo during radical radiotherapy for head and neck cancers.
-
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.
-
Efficacy of oral sucralfate suspension in prevention and treatment of chemotherapy-induced mucositis.
-
Improvement of local control of T3 and T4 nasopharyngeal carcinoma by hyperfractionated radiotherapy and concomitant chemotherapy.
-
Longitudinal evaluation of the oral mucositis weekly questionnaire-head and neck cancer, a patient-reported outcomes questionnaire.
-
Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapy.
-
NCCN Task Force Report. prevention and management of mucositis in cancer care.
-
Novel Manganese-Porphyrin Superoxide Dismutase-Mimetic Widens the Therapeutic Margin in a Preclinical Head and Neck Cancer Model.
-
Oral manifestations of chronic graft-v-host disease.
-
Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial.
-
Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia.
-
Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma.
-
Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma.
-
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
-
Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy.
-
Symptom management research in children with cancer.
-
Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.